Fresh2 Group Ltd's Cash & cash equivalent grew by 9750.74 % in the Q2 2023 sequentially, faster than Current Liabilities, this led to improvement in Fresh2 Group Ltd's Quick Ratio to 7.28 a new company high.

Within Medical Laboratories industry 8 other companies have achieved higher Quick Ratio than Fresh2 Group Ltd in second quarter 2023. While Quick Ratio total ranking has improved so far during the Q2 2023 to 847, from total ranking in the fourth quarter 2022 at 5168.

Explain Quick Ratio?
How much Cash & cash equivalents ANPC�s has?
What are ANPC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ANPC Quick Ratio	(Jun 30 2023) Q4	(Dec 31 2022) Q3	0 Q2	0 Q1	0 Q4
Y / Y Current Liabilities Change	34.65 %	-73.64 %	-14.57 %	-61.68 %	-35.55 %
Y / Y Cash & cash equivalent Change	22073.25 %	-98.6 %	-97.61 %	84.16 %	-69.2 %
Quick Ratio MRQ	7.28	0.23	0.04	0.53	0.04
ANPC's Total Ranking	# 847	# 5168	# 5132	# 5159	#
Seq. Current Liabilities Change	217.13 %	-57.54 %	139.75 %	-58.29 %	-37.92 %
Seq. Cash & cash equivalent Change	9750.74 %	125.09 %	-79.87 %	396.68 %	-99.38 %

Quick Ratio second quarter 2023 Company Ranking
Within:	No.
Medical Laboratories Industry	# 9
Healthcare Sector	# 333
Overall Market	# 847

Quick Ratio Statistics
High	Average	Low
7.28	1.45	0.04
(Jun 30 2023)		0

Financial Statements
Fresh2 Group Ltd's Current Liabilities	$ 8 Millions	Visit ANPC's Balance sheet
Fresh2 Group Ltd's Cash & cash equivalent	$ 60 Millions	Visit ANPC's Balance sheet
Source of ANPC's Sales		Visit ANPC's Sales by Geography

Cumulative Fresh2 Group Ltd's Quick Ratio

ANPC's Quick Ratio for the trailling 12 Months

ANPC Quick Ratio	(Jun 30 2023) 12 Months	(Dec 31 2022) 12 Months	0 12 Months	0 12 Months	0 12 Months
Y / Y Current Liabilities TTM Growth	-34.53 %	-47.59 %	-26.85 %	-3.16 %	49.97 %
Y / Y Cash & cash equivalent TTM Growth	11.64 %	-95.57 %	206.31 %	1519.32 %	1926.71 %
Quick Ratio TTM	3.19	0.14	1.84	2.19	1.87
Total Ranking TTM	# 5144	# 4920	# 0	# 0	#
Seq. Current Liabilities TTM Growth	12.19 %	-29.45 %	-4.06 %	-13.79 %	-10.18 %
Seq. Cash & cash equivalent TTM Growth	2394.66 %	-94.49 %	-19.59 %	1.1 %	-1.08 %

Quick ratio ranking by company, industry and sector >> Back to ANPC Financial Strength Comparisons >> Go to Compare ANPC Quick Ratio to its Competitors

On the trailing twelve months basis ANPC Cash & cash equivalent more than doubled by 22073.25 % in Q2 2023 year on year, faster than Current Liabilities, this led to increase in in Fresh2 Group Ltd's Quick Ratio to 3.19, above ANPC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 54 other companies have achieved higher Quick Ratio than Fresh2 Group Ltd. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4920 to 5144.

Explain Quick Ratio?
How much Cash & cash equivalents ANPC�s has?
What are ANPC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 55
Healthcare Sector	# 1255
Within the Market	# 5144

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.15	0.09	0.04
(Dec 31 2021)		(Dec 31 2022)

Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Medical Laboratories Industry	Quick Ratio	Jun 30 2023 MRQ Cash & cash equivalent	Jun 30 2023 MRQ Current Liabilities
Maxcyte inc	17.01	$ 216.109 Millions	$ 12.706 Millions
Somalogic Inc	15.05	$ 474.190 Millions	$ 31.501 Millions
Check Cap Ltd	11.74	$ 32.419 Millions	$ 2.762 Millions
Bioaffinity Technologies Inc	10.68	$ 8.279 Millions	$ 0.775 Millions
Viridian Therapeutics Inc	8.71	$ 247.209 Millions	$ 28.369 Millions
Omniab Inc	7.61	$ 103.149 Millions	$ 13.553 Millions
Fresh2 Group Ltd	7.28	$ 60.090 Millions	$ 8.252 Millions
Butterfly Network Inc	7.12	$ 166.806 Millions	$ 23.429 Millions
Castle Biosciences Inc	6.69	$ 225.508 Millions	$ 33.717 Millions
Guardant Health Inc	6.10	$ 1,224.849 Millions	$ 200.933 Millions
Nano X Imaging Ltd	5.62	$ 82.383 Millions	$ 14.663 Millions
Dermtech Inc	5.38	$ 86.196 Millions	$ 16.014 Millions
Personalis Inc	4.80	$ 137.207 Millions	$ 28.592 Millions
Sera Prognostics Inc	4.50	$ 63.821 Millions	$ 14.183 Millions
Exagen Inc	4.20	$ 31.466 Millions	$ 7.499 Millions
Science 37 Holdings Inc	4.07	$ 65.003 Millions	$ 15.957 Millions
Caredx Inc	3.79	$ 282.673 Millions	$ 74.496 Millions
Veracyte Inc	3.76	$ 191.142 Millions	$ 50.800 Millions
Incyte Corporation	3.07	$ 3,423.366 Millions	$ 1,115.607 Millions
Ispecimen inc	2.99	$ 8.242 Millions	$ 2.752 Millions
Absci Corp	2.81	$ 61.048 Millions	$ 21.709 Millions
Burning Rock Biotech Limited	2.43	$ 86.634 Millions	$ 35.710 Millions
Invitae Corporation	2.14	$ 325.137 Millions	$ 151.968 Millions
American Shared Hospital Services	2.04	$ 13.794 Millions	$ 6.756 Millions
Exact Sciences Corporation	1.69	$ 775.712 Millions	$ 458.185 Millions
Renalytix Plc	1.53	$ 24.700 Millions	$ 16.136 Millions
Natera Inc	1.46	$ 354.828 Millions	$ 242.518 Millions

Date modified: 2026-09-08T16:30:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.